Novartis's Big Hopes For Transplant Drug Blown Apart
Iscalimab Not Effective Enough In Preventing Kidney Rejection
Long touted as one of the drugs to watch in the Swiss giant's pipeline, iscalimab's chances of replacing tacrolimus as the standard of care preventing organ rejection in transplant patients have been dealt a hefty blow after a Phase II trial failure.
